Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cerilliant
Boehringer Ingelheim
Chubb
Citi
Cantor Fitzgerald
Fish and Richardson
US Department of Justice
Teva

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018705

« Back to Dashboard

NDA 018705 describes NITROLINGUAL PUMPSPRAY, which is a drug marketed by Pohl Boskamp and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the NITROLINGUAL PUMPSPRAY profile page.

The generic ingredient in NITROLINGUAL PUMPSPRAY is nitroglycerin. There are thirty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.
Summary for 018705
Tradename:NITROLINGUAL PUMPSPRAY
Applicant:Pohl Boskamp
Ingredient:nitroglycerin
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 018705
Ingredient-typeNitrates
Physiological EffectVasodilation
Medical Subject Heading (MeSH) Categories for 018705
Suppliers and Packaging for NDA: 018705
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NITROLINGUAL nitroglycerin AEROSOL;SUBLINGUAL 018705 NDA Jacksonville Pharmaceuticals, Inc. 70003-300 N 70003-300-20
NITROLINGUAL nitroglycerin AEROSOL;SUBLINGUAL 018705 NDA Jacksonville Pharmaceuticals, Inc. 70003-300 N 70003-300-65

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:AEROSOL;SUBLINGUALStrength0.4MG/SPRAY
Approval Date:Oct 31, 1985TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;SUBLINGUALStrength0.4MG/SPRAY
Approval Date:Jan 10, 1997TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 12, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING ANGINA PECTORIS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Daiichi Sankyo
Medtronic
Colorcon
Baxter
Express Scripts
AstraZeneca
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.